# Two New Patents — Extending Our Platform into Cancer Immunotherapy and ALDH2 Deficiency | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/344511
- Entity ID: wefunder:feed_item:344511
- Published at: 2026-06-27 19:30:18 UTC
- Updated at: 2026-06-29 10:02:41 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear WeFunder Investors and Community,A quick update on our intellectual property. In June we filed two new U.S. provisional patent applications, broadening the portfolio around Sen-Jam’s anti-inflammatory platform.SJP-015PR — immune-related adverse events (irAEs). Cancer immunotherapies (checkpoint inhibitors such as Keytruda and Opdivo) have transformed oncology, but a large share of patients develop inflammatory side effects that are usually managed with steroids — which can blunt the very anti-tumor immunity the therapy is meant to unleash. This filing covers using our combination approach to help manage those side effects through selective immune rebalancing rather than broad suppression.SJP-016PR — ALDH2 deficiency. Roughly 540 million people worldwide (about 8% of the population, and ~36% across East Asia) carry the ALDH2 variant behind the “alcohol flush” reaction — a population that also faces a markedly elevated esophageal cancer risk, with no approved product addressing either. This filing covers reducing the acute reaction, plus a forward position on lowering alcohol-associated GI cancer risk in these individuals.How this connects to AtlasEach filing takes a combination we have already tested in a completed Phase 2 trial and extends it to a new disease — matched by the specific inflammatory “loop” it interrupts. That is precisely the logic our Atlas engine is built to scale: mapping combinations of well-characterized molecules to inflammatory-loop architectures across many diseases. These patents both demonstrate that logic in action and protect the kind of loop-matched indications Atlas is designed to generate — strengthening the moat around the engine as we continue to build it.Why it matters for the portfolioBoth positions are anchored to combinations with existing Phase 2 data and tie back to our cross-program NLR biomarker patent, filed in April. They broaden our patent estate, open new therapeutic areas (and new potential partners), and deepen the IP foundation beneath the platform.→ Invest now: https://wefunder.com/senjam→ Schedule a call with me: calendly.com/jiversenThank you for your continued support.JimTo be clear and disciplined: these are early-stage (provisional) filings and forward-looking positions. Indication-specific clinical validation in these new areas still lies ahead, and our progress depends on that continued work.